Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. Co. is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. We show 1 historical shares outstanding datapoints in our OPT shares outstanding history coverage, used to compute OPT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing OPT market cap history over the course of time is important for investors
interested in comparing OPT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of OPT versus a peer is one thing; comparing
OPT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like OPT can fluctuate over the course of history.
With this page we aim to empower investors researching OPT by allowing them to research the OPT market cap history. |
Free OPT Email Alerts:
Video: The Importance of Market Cap
